AzurRx BioPharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Sapirstein
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 760 Parkside Ave Ste 304 Brooklyn NY United States of America 11226
- IPO Date
- Oct 11, 2016
- CIK
- 0001604191
- Website
- azurrx.com
- Similar Companies
- Business
- AzurRx BioPharma, Inc. (NASDAQ:AZRX) is a clinical-stage biopharmaceutical company focused on the research and development of non-systemic biologics for the treatment of gastrointestinal disorders; its core product programs include MS1819 (also known as adrulipase), a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis, FW-1022, an oral formulation of micronized niclosamide targeting gastrointestinal infections related to COVID-19, and FW-420 (or FW-ICI-AC), a niclosamide-based therapy for immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. Founded in 2014 and headquartered in Delray Beach, Florida, with prior clinical operations in Hayward, California, the company targets patient populations suffering from digestive disorders including cystic fibrosis, chronic pancreatitis, inflammatory bowel diseases, and viral GI infections. In 2021, AzurRx underwent a transformative acquisition of First Wave BioPharma for $229 million, integrating proprietary niclosamide formulations for additional inflammatory bowel disease indications such as ulcerative proctitis, ulcerative proctosigmoiditis, ulcerative colitis, and Crohn's disease, followed by a corporate name change to First Wave BioPharma, Inc. and a ticker symbol shift to FWBI; the entity maintains active trading under AZRX as of late 2025 with a market capitalization of approximately $37 million, while its former website domain now reflects Entero Therapeutics' assets including latiglutenase for celiac disease prior to that firm's unrelated rebranding to GridAI Technologies Corp. in November 2025.
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
3 Penny Stocks That Top Investors Buying Right Now
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
AzurRx BioPharma Announces Reverse Merger With First Wave Bio
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
AzurRx BioPharma Announces Reverse Stock Split
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
3 Penny Stocks That Top Investors Are Buying Right Now
AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints
AZRX Stock: The Huge Trial News Lifting Little-Known AzurRX BioPharma Today
AzurRx BioPharma Shares Increase Over 40% Pre-Market: Why It Happened
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AZRX Stock Price Increases Over 30% Pre-Market: Details You Should Know